Skip to content
Disclosery

Checkpoint Capital L.P.

Follow

13F filer, CIK 1977548, SAN FRANCISCO, CA

Checkpoint Capital L.P. reported $278,650,519 across 8 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001977548-26-000004

Period
2026-03-31
Reported value
$279M
Holdings
8
Top 10 weight
100%
New
3
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RYTMadded+235,000$20.4M
ARGXadded+11,000$8.03M
SEPNnew+100,300$2.41M
CRNXnew+40,230$1.46M
CYTKadded+13,177$868K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CORTexited-401,395-$14M
IRONreduced-166,331-$10.6M
RVMDreduced-107,461-$10.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001977548-26-000004, largest first. % of portfolio is the value over $278,650,519, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 92,500 shares; 2024Q4: 92,500 shares; 2025Q1: 115,000 shares; 2025Q2: 149,977 shares; 2025Q3: 150,000 shares; 2025Q4: 142,000 shares; 2026Q1: 153,000 shares 153,000$112M40.1%+11,000Timeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 663,381 shares; 2024Q4: 727,982 shares; 2025Q1: 907,240 shares; 2025Q2: 1,060,000 shares; 2025Q3: 763,707 shares; 2025Q4: 992,200 shares; 2026Q1: 1,227,200 shares 1,227,200$107M38.3%+235,000Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 210,000 shares; 2025Q1: 392,011 shares; 2025Q2: 280,000 shares; 2025Q3: 492,300 shares; 2025Q4: 370,000 shares; 2026Q1: 262,539 shares 262,539$25.5M9.16%-107,461Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 25,543 shares; 2024Q4: 185,000 shares; 2025Q1: 243,311 shares; 2025Q2: 265,000 shares; 2025Q3: 430,000 shares; 2025Q4: 452,992 shares; 2026Q1: 286,661 shares 286,661$18.3M6.58%-166,331Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 466,813 shares; 2024Q4: 20,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 37,587 shares; 2025Q4: 166,823 shares; 2026Q1: 180,000 shares 180,000$11.9M4.26%+13,177Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 824,878 shares; 2025Q2: 586,473 shares; 2025Q3: 283,158 shares; 2025Q4: not reported; 2026Q1: 100,300 shares 100,300$2.41M0.86%newTimeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 260,000 shares; 2025Q4: not reported; 2026Q1: 40,230 shares 40,230$1.46M0.52%newTimeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 250,000 shares; 2024Q4: 1,084,135 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 50,000 shares 50,000$596K0.21%newTimeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CORTCORCEPT THERAPEUTICS INC401,395$14Mshares
CORTCORCEPT THERAPEUTICS INC128,300$4.46Mcall

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001977548-26-000004 base2026-05-15acceptance time not in the bulk data set